Clinical Trial to Evaluate the Efficacy and Safety of TenofoBell® Tablet in Chronic Hepatitis B Patients

Chong Kun Dang Pharmaceutical78 enrolled

Overview

This study was designed to evaluate the rate of subjects with HBV DNA less than 20 IU/mL after taking TenofoBell® tablet for 48 weeks

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Chronic Hepatitis B

Interventions

ExperimentalDRUG

Experimental group are treated with TenofoBell®

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

1\. Inclusion Criteria: 1. Patients who show positive HBsAg 2. Patients who show positive or negative HBeAg 2\. Exclusion Criteria: 1. Patients who have hepatitis C(HCV), hepatitis D(HDV) or human immunodeficiency virus(HIV) 2. Patients with a history of allergic reaction to Tenofovir 3. Patients who are unable to participate in clinical trials based on investigator's decision.

Locations (1)

Daegu Chatholic University Medical center

Daegu, South Korea

Outcomes

Primary Outcomes

Rate of subjects with HBV DNA less than 20 IU/mL

Time frame: change after 48 weeks compared to baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.